Jump to content
Sclero Forums

Search the Community

Showing results for tags 'lupus research'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 6 results

  1. Full high–throughput sequencing analysis of differences in expression profiles of long noncoding RNAs and their mechanisms of action in systemic lupus erythematosus. This work determined specific lncRNAs that play important biological functions in the pathogenesis of lupus and provided a new direction for diagnosis and treatment of disease. PubMed, Arthritis Res Ther, 2019 Mar 5;21(1):70. (Also see Research on Systemic Lupus Erythematosus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Progressive reduction of serum complement levels: a risk factor for relapse in patients with hypocomplementemia in systemic lupus erythematosus (SLE). Simultaneous progressive reductions in complement levels and increases in anti-dsDNA antibody levels may indicate future relapse of serologically active clinically quiescent–SLE patients. PubMed, Lupus, 2018 Oct 11:961203318804892. (Also see Research on Systemic Lupus Erythematosus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Adipokine interactions promote the pathogenesis of systemic lupus erythematosus (SLE). Adipokines levels and associated clinical manifestations suggest involvement of adipokines in disease pathogenesis of SLE. PubMed, Cytokine, 2018 Aug 8;111:20-27. Also see Research on Systemic Lupus Erythematosus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. miR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis. The dysregulation of miR-210 levels in SLE and RA patients suggests that miR-210 might play an important role in the pathogenesis of these diseases. PubMed, Ir J Med Sci, 05/30/2017. (Also see Lupus Research and Symptoms and Complications of Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Y-27632, a Rho–associated protein kinase inhibitor, inhibits systemic lupus erythematosus. The findings showed that the inhibition of rho-associated, coiled–coil–containing protein kinase 1(ROCK) was beneficial for the prevention of systemic lupus erythematosus, which possibly by suppressing NF-κB activation. PubMed, Biomed Pharmacother, 2017 Apr;88:359-366. (Also see Interleukins and Research on Systemic Lupus Erythematosus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Serum 25–OH vitamin D level in treatment–naïve systemic lupus erythematosus (SLE) patients: Relation to disease activity, IL-23 and IL-17. Hypovitaminosis D contributes to ANA antibody production and is associated with high serum levels of IL-23 and IL-17 and may trigger the inflammatory process in SLE. Lupus, 12/07/2016. (Also see Research on Systemic Lupus Erythematosus and Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...